<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acinetobacter infection: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acinetobacter infection: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acinetobacter infection: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Zeina A Kanafani, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Souha S Kanj, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Acinetobacter</em> is a gram-negative coccobacillus that has emerged from an organism of questionable pathogenicity to an infectious agent of importance to hospitals worldwide [<a href="#rid1">1</a>]. The organism has the ability to accumulate diverse mechanisms of resistance, leading to the emergence of strains that are resistant to all commercially available antibiotics [<a href="#rid2">2</a>].</p><p><em>Acinetobacter baumannii</em> is one of the ESCAPE organisms, a group of clinically important, predominantly health care-associated organisms that have the potential for substantial antimicrobial resistance [<a href="#rid3">3,4</a>]. Other ESCAPE organisms are <em>Enterococcus faecium</em>, <em>Staphylococcus aureus</em>, <em>Clostridioides difficile</em>, <em>Pseudomonas aeruginosa</em>, and Enterobacteriaceae [<a href="#rid4">4</a>]. In addition, carbapenem-resistant <em>A. baumannii</em> is one of the critical-priority pathogens on the World Health Organization priority list of antibiotic-resistant bacteria for effective drug development [<a href="#rid5">5</a>].</p><p><em>A. baumannii </em>are included in the <em>Acinetobacter calcoaceticus baumannii </em>complex, which also includes <em>A. calcoaceticus</em>,<em> A. pittii</em>,<em> </em>and<em> A. nosocomialis. </em>For the purposes of this document, we will use the term <em>A. baumannii </em>to refer to the entire <em>A. calcoaceticus baumannii </em>complex.</p><p>The treatment and prevention of <em>Acinetobacter </em>infection will be reviewed here. The clinical features, epidemiology, microbiology, and pathogenesis of <em>Acinetobacter</em> infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/3121.html" rel="external">"Acinetobacter infection: Epidemiology, microbiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANTIBIOTIC RESISTANCE</span><span class="headingEndMark"> — </span><em>Acinetobacter </em>has the ability to develop resistance through several diverse mechanisms, which has led to emergence of strains that are resistant to all commercially available antibiotics [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H688212198"><span class="h2">Definitions</span><span class="headingEndMark"> — </span>In 2011, a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the United States Centers for Disease Control and Prevention (CDC) proposed specific definitions for characterizing drug resistance in organisms that cause many health care-associated infections, and, in 2022, the CDC updated the definition of multidrug resistance [<a href="#rid6">6,7</a>]. For <em>Acinetobacter</em>, the following definitions were established based on the extent of resistance to antibiotics that would otherwise serve as treatments for <em>Acinetobacter </em> (<a class="graphic graphic_table graphicRef109974" href="/d/graphic/109974.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidrug-resistant</strong> – Isolate is nonsusceptible to at least one agent in three or more antibiotic groups (ie, third- or fourth-generation cephalosporins, fluoroquinolones, aminoglycosides, carbapenems, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extensively drug-resistant</strong> – Isolate is nonsusceptible to at least one agent in all but two or fewer antibiotic classes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbapenem-resistant</strong> – Isolate is nonsusceptible to at least one antipseudomonal carbapenem.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pandrug-resistant</strong> – Isolate is nonsusceptible to all agents.</p><p></p><p>Prior to this publication, there was no standard definition for the term "multidrug resistant," which partly accounts for the significant heterogeneity of clinical studies evaluating various regimens for drug-resistant <em>Acinetobacter </em>infections.</p><p class="headingAnchor" id="H3"><span class="h2">Epidemiology and risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology of resistant strains</strong> – Globally, resistant strains have become increasingly common causes of nosocomial infections since the 1980s [<a href="#rid8">8-29</a>]. In a 2009 report of surveillance data from more than 100 centers worldwide, 61 percent of <em>Acinetobacter</em> isolates were resistant to <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> and 67 percent were resistant to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid30">30</a>]. These results are significantly worse than those published in 2007 from the same reporting system (34 and 40 percent resistance, respectively) [<a href="#rid9">9</a>]. Carbapenem and <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> resistance increased as well (from 10 percent to 54 percent for carbapenems, and 8 to 41 percent for tobramycin).</p><p></p><p class="bulletIndent1">A more recent global analysis of over 4300 <em>A. baumannii </em>isolates identified between 2016 and 2018 found significant regional variation in rates of resistance [<a href="#rid31">31</a>]. Overall global resistance to <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> was 67 percent, with the highest rate (83 percent) in the Africa/Middle East region. Similar variation was noted for <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> and <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, for which global resistance rates were 71 and 57 percent, respectively, with the highest resistance rates for levofloxacin found in Africa/Middle East (85 percent) and in Latin America for amikacin (72 percent). North America was the only region with resistance rates below 50 percent for meropenem (36 percent), levofloxacin (45 percent), and amikacin (22 percent). <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">Colistin</a> resistance was below 7 percent in all regions of the world.</p><p></p><p class="bulletIndent1">In the United States, the emergence of resistance among <em>Acinetobacter</em> strains has also been demonstrated by analysis of The Surveillance Network, an electronic passive surveillance database that collects information from clinical laboratories across the United States [<a href="#rid32">32</a>]. Multidrug resistance, defined as nonsusceptibility to at least one agent in three or more antibiotic groups (excluding fluoroquinolones), increased from 21 percent during 2003 to 2005 to 35 percent during 2009 to 2012 [<a href="#rid33">33</a>]. Resistance to carbapenems more than doubled during this time, from 21 to 48 percent.</p><p></p><p class="bulletIndent1">The rising prevalence of antimicrobial resistance among <em>A. baumannii</em> isolates has influenced the epidemiology of serious hospital-acquired infections. In a systematic review, carbapenem-resistant and multidrug-resistant <em>A. baumannii</em> accounted for 65 and 59 percent, respectively, of all hospital-acquired infections among intensive care unit patients in Southeast Asia [<a href="#rid34">34</a>]. In some countries in the Arab League, multidrug-resistant <em>A. baumannii</em> is the most common cause of ventilator-associated pneumonia [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Independent risk factors for colonization or infection with resistant strains of <em>Acinetobacter</em> include the following [<a href="#rid16">16,36-40</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior colonization with methicillin-resistant <em>S. aureus</em> (MRSA)</p><p class="bulletIndent2"><span class="glyph">•</span>Prior beta-lactam use, particularly carbapenems</p><p class="bulletIndent2"><span class="glyph">•</span>Prior fluoroquinolone use</p><p class="bulletIndent2"><span class="glyph">•</span>Bedridden status</p><p class="bulletIndent2"><span class="glyph">•</span>Current or prior intensive care unit admission</p><p class="bulletIndent2"><span class="glyph">•</span>Presence of a central venous catheter</p><p class="bulletIndent2"><span class="glyph">•</span>Recent surgery</p><p class="bulletIndent2"><span class="glyph">•</span>Mechanical ventilation</p><p class="bulletIndent2"><span class="glyph">•</span>Hemodialysis</p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy</p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoid therapy</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Mechanisms of resistance</span><span class="headingEndMark"> — </span><em>Acinetobacter</em> species are capable of accumulating multiple antibiotic resistance genes, leading to the development of multidrug-resistant or extensively drug-resistant strains [<a href="#rid41">41,42</a>]. Frequently expressed resistance mechanisms in nosocomial strains of <em>Acinetobacter</em> include beta-lactamases, alterations in cell wall channels (porins), and efflux pumps:</p><p class="bulletIndent1"><span class="glyph">●</span>AmpC beta-lactamases are chromosomally encoded cephalosporinases intrinsic to all <em>A. baumannii</em>. Usually, such beta-lactamases have a low level of expression that does not cause clinically appreciable resistance; however, the addition of a promoter insertion sequence ISAba1 next to the AmpC gene increases beta-lactamase production, causing resistance to cephalosporins [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">The most troubling clinical resistance mechanism has been the acquisition of beta-lactamases in <em>Acinetobacter</em>, including serine and metallo-beta-lactamases, which confer resistance to carbapenems [<a href="#rid44">44</a>]. Acquired extended-spectrum beta-lactamase carriage occurs in <em>Acinetobacter</em> but is not as widespread as in <em>Klebsiella pneumoniae</em> or <em>Escherichia coli</em> [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases"</a> and  <a class="medical medical_review" href="/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Porin channels in <em>A. baumannii</em> are poorly characterized; it is known that reduced expression or mutations of bacterial porin proteins can hinder passage of beta-lactam antibiotics into the periplasmic space, leading to antibiotic resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overexpression of bacterial efflux pumps can decrease the concentration of beta-lactam antibiotics in the periplasmic space. To cause clinical resistance in <em>Acinetobacter</em>, efflux pumps usually act in association with overexpression of AmpC beta-lactamases or carbapenemases. Efflux pumps can remove beta-lactam antibiotics as well as quinolones, tetracyclines, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, and <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> [<a href="#rid46">46</a>].</p><p></p><p><em>A. baumannii</em> can become resistant to quinolones through mutations in the genes <em>gyrA</em> and <em>parC</em> and can become resistant to aminoglycosides by expressing aminoglycoside-modifying enzymes [<a href="#rid44">44</a>].</p><p>The mechanism of resistance of <em>Acinetobacter</em> to <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> appears to be associated with a mutation in the genes encoding the PmrA and B proteins; additional regulatory factors remain to be determined [<a href="#rid47">47</a>].</p><p>Heteroresistance, characterized by resistant subpopulations within a single strain, has been described in <em>Acinetobacter</em> strains [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Heteroresistance'</a>.)</p><p class="headingAnchor" id="H3707510431"><span class="h1">CONSIDERATIONS PRIOR TO SELECTING AN ANTIBIOTIC REGIMEN</span></p><p class="headingAnchor" id="H3902381671"><span class="h2">Differentiating colonization from infection</span><span class="headingEndMark"> — </span><em>Acinetobacter</em> can be readily identified on culture of relevant clinical specimens. However, differentiating colonization from true infection can be challenging and depends on the anatomic site from which the culture sample was obtained and the patient's clinical presentation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cultures from sterile sites</strong> – Growth of the organism from normally sterile sites (eg, blood, pleural fluid, peritoneal fluid, cerebrospinal fluid) should be interpreted as representing true infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cultures from nonsterile sites</strong> – <em>Acinetobacter </em>frequently causes colonization, especially among patients with prolonged hospitalizations. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1">Clinical evaluation of the patient is necessary to determine whether a positive culture from a nonsterile site represents true infection. Colonization should not be treated, because inappropriate antibiotic use contributes to added adverse effects and selects for resistant organisms.</p><p></p><p class="bulletIndent1">Patients with clinical evidence of pneumonia (eg, new pulmonary infiltrate, decreased oxygenation, and fever and/or leukocytosis) whose respiratory culture grows <em>Acinetobacter</em> should be considered to have true infection. In the absence of consolidation on chest radiography and other clinical signs of pulmonary infection, respiratory growth of <em>Acinetobacter</em> probably represents colonization rather than invasive disease.</p><p></p><p class="bulletIndent1">Asymptomatic bacteruria should not be treated in most individuals, including those with urinary catheters. Further discussion can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/8061.html" rel="external">"Asymptomatic bacteriuria in adults"</a>.)</p><p></p><p class="bulletIndent1">Cultures from other nonsterile sites, such as wounds, should also undergo clinical scrutiny. In the absence of clinical evidence of infection, such as fever, leukocytosis, or localized inflammation or purulence, the culture findings may be presumed to reflect colonization rather than infection.</p><p></p><p class="headingAnchor" id="H1114939639"><span class="h2">Indications for empiric therapy</span><span class="headingEndMark"> — </span>In select cases, we suggest empiric treatment for possible <em>Acinetobacter</em> infection. Primarily, we provide empiric therapy to patients with moderate to severe infection (eg, ventilator-associated pneumonia, urosepsis) who have had prior cultures at the site of infection that grew <em>Acinetobacter</em>. In such cases, a combination of antibiotics should be chosen that were active against the prior isolates. If the organism ultimately grows from culture, we alter our regimen once susceptibility results return, as described below. (See <a class="local">'Suggested antibiotic regimens'</a> below.)</p><p class="headingAnchor" id="H3759931695"><span class="h2">Determining the likelihood of resistance</span><span class="headingEndMark"> — </span>The likelihood of resistance should be assessed prior to selecting empiric antibiotics to treat <em>Acinetobacter </em>infections. Factors that can predict resistance include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>The patient's prior culture results</strong> – Patients with prior cultures that grew multidrug-resistant <em>Acinetobacter </em>are likely to have ongoing resistance. For such patients, empiric antibiotic selection should include agents effective against the prior isolates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The patient's prior antibiotic exposure</strong> – Patients who have received broad-spectrum antibiotics prior to developing an <em>Acinetobacter </em>infection have an increased likelihood of resistance to those antibiotics. In these situations, antibiotics from a different class should be chosen for empiric therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local resistance rates</strong> – Elevated local rates of resistance of <em>Acinetobacter </em>isolates may predict resistance in individual patients. If local resistance rates to beta-lactams, carbapenems, fluoroquinolones, and aminoglycosides are higher than 10 to 15 percent, a highly resistant pathogen should be suspected, and empiric therapy should be altered accordingly.</p><p></p><p class="headingAnchor" id="H4095568539"><span class="h2">Severity of infection</span><span class="headingEndMark"> — </span>When making treatment decisions, we generally divide <em>Acinetobacter</em> infections into one of two categories: mild versus moderate to severe. Clinical judgment is of paramount importance when making these distinctions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild infections</strong> – In the absence of severe sepsis or septic shock, we generally categorize urinary tract infections (UTIs) and skin and soft tissue infections as mild as long as source control is achieved (eg, removal of urinary catheter, debridement of infected soft tissue), if applicable. Select cases of pneumonia may be categorized as mild if no systemic symptoms (eg, fever &gt;100.5°F/38°C, tachycardia, tachypnea), hypoxia, mechanical ventilation, or other concerning features are present; some providers may label this syndrome as "tracheitis" as opposed to pneumonia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe infections</strong> – Moderate to severe infections include any infection for which heightened clinical concern is present or the criteria for mild infection are not met. Examples include severe sepsis or septic shock; infections for which source control has not been achieved (eg, foreign material is retained, abscess is not drained); or any infection other than UTI, skin and soft tissue infection, or mild pneumonia.</p><p></p><p class="headingAnchor" id="H1768507054"><span class="h1">SUGGESTED ANTIBIOTIC REGIMENS</span><span class="headingEndMark"> — </span>Antibiotic options for treatment of <em>Acinetobacter </em>are limited due to high rates of resistance. (See <a class="local">'Antibiotic resistance'</a> above.)</p><p>Our suggested antibiotics are divided into two groups: first-line antibiotics and second-line antibiotics. In general, first-line antibiotics are preferred for susceptible isolates and include beta-lactam antibiotics, carbapenems, and fluoroquinolones (as well as aminoglycosides for urinary tract infections [UTIs]). Second-line agents include polymyxins (ie, <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> and <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a>) and <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivatives (eg, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>) and are reserved for resistant isolates. Details regarding specific antibiotics are discussed below. (See <a class="local">'Antibiotic efficacy and safety'</a> below.)</p><p>Prior to selecting an antibiotic regimen, certain factors should be considered including the likelihood of resistance and indications for empiric therapy, as described above (see <a class="local">'Indications for empiric therapy'</a> above and <a class="local">'Determining the likelihood of resistance'</a> above). Additionally, the anatomic site of infection (eg, pneumonia, bacteremia, meningitis, osteomyelitis) may alter antibiotic selection and is discussed below. (See <a class="local">'Disease-specific considerations'</a> below.)</p><p>Our suggested regimens depend primarily on severity of illness, as defined above (see <a class="local">'Severity of infection'</a> above). Other considerations include patient drug allergies or intolerances, need to cover additional infections, and hospital formulary. In general, our approach is consistent with those of expert guidelines [<a href="#rid49">49,50</a>].</p><p>Detailed regimens are outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a>) and dosing recommendations are listed in the table  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2707125386"><span class="h2">Mild infections</span><span class="headingEndMark"> — </span>For mild infection, we typically suggest monotherapy based on the results of the isolate's antibiotic susceptibility testing. An active first-line agent (ie, a beta-lactam antibiotic, carbapenem, or fluoroquinolone) is preferred over a second-line agent (a polymyxin or <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative). An aminoglycoside or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> can be used as monotherapy for susceptible UTIs. For simple cystitis, some experts try <a class="drug drug_general" data-topicid="8477" href="/d/drug information/8477.html" rel="external">fosfomycin</a> although its efficacy is debatable. Regimens, doses, and supportive data are outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a>), table  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>), and elsewhere. (See <a class="local">'Antibiotic efficacy and safety'</a> below.)</p><p>If susceptibility results are not yet available or empiric therapy is indicated, the likelihood of resistance should determine the regimen selection (see <a class="local">'Determining the likelihood of resistance'</a> above). If resistance is unlikely, we suggest monotherapy with a first-line agent. If resistance is likely, we suggest treating with combination therapy using our suggested regimen for empiric therapy of moderate to severe infections, as described below (see <a class="local">'Moderate to severe infections'</a> below). Once results of antimicrobial susceptibility are available, a regimen can be chosen from among the active agents.</p><p class="headingAnchor" id="H1040094140"><span class="h2">Moderate to severe infections</span><span class="headingEndMark"> — </span>We suggest initial combination therapy for all moderate to severe infections, and the choice of agents is based on the results of the isolate's antibiotic susceptibility testing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolates for which susceptibility results are available</strong> – Detailed regimen selections and doses are seen in the algorithm  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a>) and table  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Isolates susceptible to one or more first-line agents</strong> – For isolates susceptible to more than one first-line agent, we combine two active first-line agents from different classes (ie, a beta-lactam antibiotic or carbapenem with either a fluoroquinolone or aminoglycoside, or a fluoroquinolone with an aminoglycoside).</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="141569" href="/d/drug information/141569.html" rel="external">Sulbactam-durlobactam</a> is a newer first-line beta-lactamase inhibitor antibiotic combination that should be reserved for use only in patients with <em>A. baumannii </em>hospital-acquired or ventilator-associated pneumonia or bacteremia whose isolate is resistant to other first-line agents, as discussed below. (See <a class="local">'First-line antibiotics'</a> below.)</p><p></p><p class="bulletIndent2">For isolates susceptible to only one first-line agent, we combine the active first-line agent with a second-line agent to which the isolate is susceptible. To prevent additive adverse effects, we avoid combining beta-lactam antibiotics with carbapenems. We also avoid combining polymyxins with carbapenems (unless a third agent is added) because data suggest lack of benefit of this combination compared with <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> monotherapy [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>I<strong>solates resistant to all first-line agents</strong> – For isolates resistant to all first-line agents, we favor combining two active second-line agents (ie, a polymyxin and a <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative [either <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> or <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>]), if possible.</p><p></p><p class="bulletIndent2">For isolates susceptible to only a <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative and an aminoglycoside, we combine those two agents.</p><p class="bulletIndent2">For isolates only susceptible to one second-line agent or an aminoglycoside, we generally favor triple therapy that includes the one active agent with two agents to which the isolate is resistant. Specifically, we combine the only active agent (ie, the active polymyxin, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative, or aminoglycoside) with high-dose extended-infusion <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> and high-dose extended-infusion <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>. For isolates susceptible to <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">cefiderocol</a> in these situations, some experts may replace the meropenem with cefiderocol, although data supporting its use are lacking. Some experts may consider replacing the ampicillin-sulbactam with <a class="drug drug_general" data-topicid="141569" href="/d/drug information/141569.html" rel="external">sulbactam-durlobactam</a>. We avoid the combination of a polymyxin and an aminoglycoside, unless there are no other options, due to increased risk of renal toxicity.</p><p></p><p class="bulletIndent2">For isolates resistant to all antibiotics, data are extremely limited, and the optimal approach is uncertain. In such cases, we often administer triple therapy with high-dose extended-infusion <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> plus two of the following: a high-dose extended infusion of <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, a polymyxin, or a <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative. If <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">cefiderocol</a> is the only active agent, some experts would include it in the regimen. Some experts may consider replacing the ampicillin-sulbactam with <a class="drug drug_general" data-topicid="141569" href="/d/drug information/141569.html" rel="external">sulbactam-durlobactam</a>. Outcomes with these regimens are uncertain.</p><p></p><p class="bulletIndent2">Consultation with an expert is advised for these infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolates for which empiric therapy is indicated or susceptibility results are pending</strong> – For these, we generally combine either <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> or a carbapenem with a first- or second-line agent, depending on the suspected susceptibility profile of the isolate. Due to data suggesting a lack of benefit, we avoid combining polymyxins with carbapenems (unless a third agent is added) [<a href="#rid51">51</a>]. Once results of antimicrobial susceptibility results are available, a regimen can be chosen from among the active agents  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>).</p><p></p><p>The rationale for combination therapy is discussed below. (See <a class="local">'Role of combination antibiotic therapy'</a> below.)</p><p>For most infections, we transition combination therapy to monotherapy once clinical improvement occurs. However, for primary bloodstream infections, severe pneumonia, and severe intra-abdominal infections, we continue combination therapy for the full course of therapy.</p><p class="headingAnchor" id="H5"><span class="h1">ANTIBIOTIC EFFICACY AND SAFETY</span><span class="headingEndMark"> — </span>Inherent and acquired resistance limits the number of antimicrobial options for <em>Acinetobacter</em>. Very few trials have evaluated the efficacy and safety of different antimicrobial regimens for <em>Acinetobacter</em> infections, and most available data for <em>Acinetobacter </em>infections are derived from in vitro studies and observational series. Most of these studies, however, are limited by their small sample sizes, variability in the severity of disease and comorbidities in the included patients, and the lack of a comparator group.</p><p class="headingAnchor" id="H688208201"><span class="h2">First-line antibiotics</span><span class="headingEndMark"> — </span>Infections caused by antibiotic-susceptible <em>Acinetobacter</em> isolates may have several first-line therapeutic options, including broad-spectrum cephalosporins (<a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>), <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, carbapenems (eg, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> or imipenem-cilastatin), and fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>). Aminoglycosides and <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> are also acceptable first-line agents for infections isolated to the urinary tract.</p><p>We often use one of these agents for monotherapy or as part of combination therapy depending on the severity of illness. Specific antibiotic regimens are discussed above and in the algorithm  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>). (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-lactam antibiotics</strong> – Five beta-lactam antibiotics often have activity against <em>Acinetobacter</em>: <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, and <a class="drug drug_general" data-topicid="141569" href="/d/drug information/141569.html" rel="external">sulbactam-durlobactam</a>.</p><p></p><p class="bulletIndent1">There are no data comparing these agents to each other, so one agent is not preferred over the others. However, <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> and <a class="drug drug_general" data-topicid="141569" href="/d/drug information/141569.html" rel="external">sulbactam-durlobactam</a> sometimes retain activity against multidrug-resistant isolates, so we typically reserve them for infections resistant to other first-line agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">Ampicillin-sulbactam</a> – This antibiotic is unique because the sulbactam component (a beta-lactam with beta-lactamase inhibitor activity) of the combination drug has excellent stand-alone bactericidal activity against <em>Acinetobacter </em>even in the absence of <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>. The unique mechanism of action of sulbactam can preserve its activity when resistance to other beta-lactam antibiotics and carbapenems is present [<a href="#rid52">52,53</a>]. In the United States and many other countries, sulbactam is available only in combination with ampicillin [<a href="#rid54">54-56</a>].</p><p></p><p class="bulletIndent2">Dosing recommendations for <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> vary among experts. For highly resistant <em>Acinetobacter </em>infections, some published reports used higher doses than typically recommended by the manufacturer [<a href="#rid57">57-59</a>]. Our dosing suggestions, which are based on severity of illness, can be found in the table  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>) and generally match those of published guidelines [<a href="#rid49">49,50</a>].</p><p></p><p class="bulletIndent2">Limited retrospective studies comparing <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> to other active agents (eg, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>, a polymyxin) as monotherapy or part of combination therapy for treatment of <em>Acinetobacter </em>infections suggest that ampicillin-sulbactam is at least as effective as alternative agents. In the studies, clinical success rates for ampicillin-sulbactam ranged from 83 to 93 percent [<a href="#rid54">54,55,60,61</a>].</p><p></p><p class="bulletIndent2">For carbapenem-resistant <em>Acinetobacter </em>infections, two meta-analyses have evaluated various treatment regimens. One meta-analysis of 18 studies and over 1800 patients found that combination therapy that included <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> (with daily doses of at least 18 g per day) reduced mortality and had less nephrotoxicity in critically ill patients compared with colistin-based regimens [<a href="#rid62">62</a>]. Another meta-analysis of 23 studies and over 2100 patients found that sulbactam-containing regimens reduced mortality compared with polymyxin-based or tigecycline-based regimens [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2">For moderate to severe infections with extensive drug resistance, we sometimes use high-dose prolonged-infusion <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> in combination regimens even if the isolate is reported as resistant. The rationale for this practice is based on pharmacokinetics that suggest that high doses of sulbactam can overcome the molecular mechanisms of resistance [<a href="#rid57">57,64</a>]. Limited clinical data support this approach for <em>Acinetobacter </em>infections, so it is reserved for infections for which very few active antibiotics are available. More information regarding prolonged infusions can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/97446.html" rel="external">"Prolonged infusions of beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="141569" href="/d/drug information/141569.html" rel="external">Sulbactam-durlobactam</a> – Sulbactam-durlobactam is a newer beta-lactam/beta-lactamase inhibitor combination that was developed specifically to treat <em>Acinetobacter </em>spp. In vitro, it is highly active against <em>A. baumannii</em>,<em> </em>exhibiting a 32-fold reduction in MIC<sub>90</sub> compared with sulbactam alone [<a href="#rid65">65</a>]. In 2023, based on clinical data, it was approved by the United States Food and Drug Administration (FDA) for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP, respectively) due to carbapenem-resistant strains of <em>A. </em>baumannii that are susceptible to sulbactam-durlobactam. </p><p></p><p class="bulletIndent2">The primary study used for FDA approval of <a class="drug drug_general" data-topicid="141569" href="/d/drug information/141569.html" rel="external">sulbactam-durlobactam</a> was a randomized trial conducted at 59 clinical sites in 16 countries from 2019 to 2021 [<a href="#rid66">66</a>]. A total of 125 patients with infection due to carbapenem-resistant <em>A. baumannii</em> (122 with HAP or VAP, and 3 with bacteremia) were randomized to imipenem-cilastatin plus either sulbactam-durlobactam or <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> and were followed for 28 days. Twelve of 63 patients (19 percent) in the sulbactam-durlobactam group died within 28 days from any cause, compared with 20 of 62 (32 percent) in the colistin group (difference -13.2percent; 95% CI -30.0 to 3.5 percent). The rate of clinical cure was 62 percent in the sulbactam-durlobactam group compared with 40 percent in the colistin group (difference 22 percent; 95% CI 2.9 to 40.3 percent), and rate of microbiologic eradication of the organism at the end of therapy was 86 percent in the sulbactam-durlobactam group compared with 61 percent in the colistin group (difference 24 percent; 95% CI 7.9 to 40.9 percent). Nephrotoxicity was lower in the sulbactam-durlobactam group compared with the colistin group (12 versus 32 percent, respectively).</p><p></p><p class="bulletIndent2">Because of its activity against highly-resistant isolates and limited clinical data, we reserve this agent for patient<em>s with A. baumannii </em>hospital-acquired or ventilator-associated pneumonia or bacteremia whose isolate is resistant to other first-line agents. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other first-line agents</strong> – <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">Ceftazidime</a>, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, and <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> have less data to support their use, but they have been used extensively in clinical practice. We routinely use them to treat infections caused by susceptible isolates.</p><p></p><p class="bulletIndent1">The adverse effects of beta-lactams are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbapenems</strong> – Certain carbapenems (ie, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>) are highly bactericidal against susceptible strains of <em>Acinetobacter </em>[<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">Because isolates that are susceptible to <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> may be resistant to <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> and vice versa, susceptibility to specific carbapenems should be confirmed prior to use [<a href="#rid67">67,68</a>]. <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">Ertapenem</a> has little intrinsic activity against<em> Acinetobacter</em> and should not be used [<a href="#rid69">69-71</a>].</p><p></p><p class="bulletIndent1">The clinical cure rates with <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> for ventilator-associated pneumonia due <em>to Acinetobacter</em> range from 57 to 83 percent in small series [<a href="#rid46">46-48,60</a>]. For bacteremia, one small case series reported successful clinical outcome in 56 percent of individuals treated with imipenem [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1">For severe infections or infections with elevated minimum inhibitory concentrations (MICs) for <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> (ie, MIC of 4 or 8 mcg/mL), higher doses and prolonged infusions of meropenem are often used to improve pharmacodynamics by increasing the time above MIC. Limited clinical data support this approach for <em>Acinetobacter </em>infections, so it is reserved for infections for which very few active antibiotics are available [<a href="#rid72">72-74</a>]. More information regarding prolonged infusions can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/97446.html" rel="external">"Prolonged infusions of beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluoroquinolones</strong> – <em>Acinetobacter </em>isolates are sometimes susceptible to one or more fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>) [<a href="#rid75">75,76</a>]. A benefit of the fluoroquinolones is that they are available in both oral and parenteral formulations. Data are limited regarding their use for treatment of <em>Acinetobacter</em> infections, but they are commonly used to treat susceptible isolates. Susceptibility breakpoints are available only for ciprofloxacin and levofloxacin [<a href="#rid77">77,78</a>]. (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminoglycosides</strong> – Aminoglycosides (eg, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>) often exhibit in vitro activity against <em>Acinetobacter </em>[<a href="#rid79">79,80</a>]. These antibiotics are first-line agents as monotherapy for urinary tract infections (UTIs) without associated bacteremia because they achieve high urine concentrations. However, outside the urinary tract, data are limited, and we suggest not using them unless they are used as part of a combination regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> – This agent is an option for UTIs, although most <em>Acinetobacter </em>isolates are resistant [<a href="#rid81">81</a>]. We use trimethoprim-sulfamethoxazole for treatment of UTIs without severe sepsis or bacteremia and only if the urine isolate is reported to be susceptible. Due to lack of clinical data, we do not use it as part of combination regimens. Further details regarding use of trimethoprim-sulfamethoxazole for UTIs are found elsewhere. (See  <a class="medical medical_review" href="/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females", section on 'Directed antimicrobial selection'</a> and  <a class="medical medical_review" href="/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Regimen selection'</a>.)</p><p></p><p>Emergence of resistance to first-line agents during therapy has been observed, especially when used as single agents [<a href="#rid10">10,82</a>]. For this reason, these agents are sometimes used in combination for serious infections, as described below [<a href="#rid67">67,68</a>]. (See <a class="local">'Role of combination antibiotic therapy'</a> below.)</p><p class="headingAnchor" id="H688212264"><span class="h2">Second-line antibiotics</span><span class="headingEndMark"> — </span>In the setting of resistance to the first-line agents, therapeutic options are limited. Polymyxins (ie, <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> and <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a>) and certain <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivatives (ie, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>) are the main therapeutic options for extensively drug-resistant <em>Acinetobacter</em>.</p><p>We consider polymyxins to be second-line agents because of their adverse effects and complex dosing. Tetracycline-based antibiotics have less concerning adverse effects but have limited distribution in certain tissues. In general, clinical experience with both classes of antibiotics is less than with beta-lactam antibiotics and fluoroquinolones.</p><p>Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>). We sometimes use one of these agents for monotherapy or as part of combination therapy depending on the severity of illness and susceptibility profile of the isolate.</p><p>Specific regimens and suggested doses are summarized above and in the algorithm  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a>) and table  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>). (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polymyxins</strong> – Polymyxins (<a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> and <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> [polymyxin E]) are commonly used for <em>Acinetobacter</em> isolates resistant to first-line agents.</p><p></p><p class="bulletIndent1">The dose for <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> and <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> depends on the formulation available, which varies by geographic region. In addition to variable dosing algorithms based on formulation, serum levels can vary among individuals treated with the same agent following the same dosing algorithm. Expert panels recommend drug level monitoring during treatment, although these tests are not universally available [<a href="#rid83">83</a>]. Details regarding dosing of polymyxins are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/486.html" rel="external">"Polymyxins: An overview", section on 'Intravenous administration'</a>.)</p><p></p><p class="bulletIndent1">Clinical data comparing <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> to <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> are limited. In general, for infections outside the urinary tract and lung, polymyxin B is favored because pharmacokinetic studies suggest that it achieves adequate drug levels more rapidly and reliably than colistin [<a href="#rid83">83</a>]. For infections limited to the urinary tract, colistin is generally preferred because it converts to its active form and reaches high concentrations in the urinary tract. For pneumonia, neither agent is recommended as parenteral monotherapy due to low drug concentrations in the lung [<a href="#rid84">84,85</a>]. Often, in clinical practice, only one of the two agents is available, so they are sometimes used interchangeably. Further details regarding when we use these agents are found elsewhere. (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p></p><p class="bulletIndent1">Susceptibility breakpoints for the polymyxins differ among guidelines from the United States and Europe. Most evidence suggests that MICs &gt;2 mcg/mL reduce the antimicrobial effect of polymyxins [<a href="#rid86">86</a>]. More details regarding susceptibility breakpoints are found elsewhere. (See  <a class="medical medical_review" href="/d/html/486.html" rel="external">"Polymyxins: An overview", section on 'Susceptibility testing'</a>.)</p><p></p><p class="bulletIndent1">Although polymyxins usually have in vitro activity against <em>Acinetobacter </em>[<a href="#rid87">87,88</a>], resistance has been observed, including emergence of resistance while on therapy [<a href="#rid86">86,89,90</a>]. Resistance rates of 2.7 percent in Europe and 1.7 percent in North and Latin America have been reported [<a href="#rid89">89</a>]. In the United States, <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> resistance was 6.9 percent during 2009 to 2012 [<a href="#rid33">33</a>]. Heteroresistance, in which there is a resistant subpopulation detected within an otherwise susceptible population, has also been observed [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1">There are no randomized trials addressing the efficacy of polymyxins for treatment of <em>Acinetobacter</em> infections. Some observational studies suggest that outcomes with polymyxins may be similar to other regimens [<a href="#rid92">92-94</a>]. In a meta-analysis of six studies of 359 patients with ventilator-associated pneumonia due mainly to <em>A. baumannii</em> but also <em>P. aeruginosa</em>, clinical outcomes with intravenous <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> were similar to those observed with a carbapenem or high-dose <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> [<a href="#rid94">94</a>]. The overall clinical response rate for colistin was 66 percent.</p><p></p><p class="bulletIndent1">Nephrotoxicity is the most concerning adverse effect associated with systemic <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> and has been reported in up to 36 percent of patients [<a href="#rid95">95</a>], although, in the meta-analysis above, intravenous colistin use was not associated with excess renal dysfunction compared with the other agents evaluated [<a href="#rid94">94</a>]. Colistin dosing depends on the available preparation and should be adjusted in patients with impaired renal function. <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">Polymyxin B</a> is associated with lower rates of nephrotoxicity than colistin and does not need to be dose adjusted for renal function. Neurotoxicity, primarily paresthesias, is another important side effect and is relatively uncommon. (See  <a class="medical medical_review" href="/d/html/486.html" rel="external">"Polymyxins: An overview", section on 'Adverse reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">Tetracycline</a><strong> derivatives</strong> – Antibiotics within the tetracycline class (eg, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>) often have activity against <em>Acinetobacter </em>[<a href="#rid96">96-98</a>].</p><p></p><p class="bulletIndent1">In general, we use these agents as monotherapy only for mild skin and soft tissue infections or mild pneumonia. We favor combination therapy for all other sites of infection and for more severe infections. The <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> class is avoided as monotherapy for urinary tract infections and bacteremia because they rapidly enter tissues following administration, which results in low urine and serum levels [<a href="#rid52">52</a>]. Further details regarding when we use these agents are found above and in the algorithm and table  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>). (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p></p><p class="bulletIndent1">There are no data comparing these agents to each other.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">Minocycline</a> – Many resistant strains of<em> A. baumannii</em> are susceptible in vitro to minocycline, which can be given intravenously or orally [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent2">In vitro susceptibility to <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> can be inferred from susceptibility to <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>. In addition, some tetracycline-resistant strains remain susceptible to minocycline, so it is worthwhile to ask the microbiology laboratory to determine susceptibility to minocycline for tetracycline-resistant isolates. Among nearly 5500 <em>A. baumannii</em> strains collected from medical centers worldwide from 2007 to 2011, 79 percent were susceptible to minocycline compared with 30 and 60 percent to tetracycline and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, respectively [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent2">Limited clinical experience suggests favorable outcomes with <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, as monotherapy or in combination [<a href="#rid100">100</a>]. In a review of retrospective case series in which minocycline was used for multidrug-resistant <em>A. baumannii</em> infections (predominantly ventilator-associated pneumonia), successful clinical and microbiologic outcomes were reported for most patients [<a href="#rid101">101</a>]. As an example, in a retrospective study of patients with ventilator-associated carbapenem-resistant <em>A. baumannii</em> pneumonia, the clinical response rate was 80 percent among the 19 who were treated with minocycline as monotherapy or as part of a combination regimen [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent2">Overall, both intravenous and oral <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> are well-tolerated, but, like other agents in the <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> class, they can cause photosensitivity and gastrointestinal side effects [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/d/html/494.html" rel="external">"Tetracyclines", section on 'Adverse reactions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> – This agent may be more available than the other <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivatives in some hospitals and pharmacies. However, less clinical data are available to support doxycycline compared with <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> [<a href="#rid103">103</a>]. Studies suggest that susceptibility of <em>A. baumannii </em>to doxycycline is above 50 percent, at least in some locales. For example, among 93 isolates from a hospital in India, 64 (69 percent) were susceptible [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent2">However, in a study of over 5400 isolates <em>of A. baumannii </em>collected from hospitals around the world, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> was estimated to be two-fold more potent than <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> [<a href="#rid99">99</a>]. Susceptibility rates were also lower for doxycycline (60 percent) than for minocycline (79 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">Tigecycline</a> – Tigecycline has activity against some multidrug- and extensively resistant strains of <em>A. baumannii</em>, although clinical experience is limited [<a href="#rid46">46,53,89,105-111</a>]. Tigecycline is only available in parenteral formulation.</p><p></p><p class="bulletIndent2">Unlike <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, susceptibility breakpoints for <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> are not available for <em>Acinetobacter </em>isolates. Furthermore, in vitro susceptibility to tigecycline cannot be inferred from susceptibility to <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> or any other tetracyclines. We generally consider isolates with an MIC ≤0.5 mg/L to be susceptible and isolates with MICs &gt;0.5 mg/L to be resistant, based on European standards for Enterobacterales [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent2">We use different dosages of <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> depending on the clinical syndrome and severity of illness  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>). A retrospective study suggested that tigecycline was well tolerated at higher than standard doses in critically ill patients with multidrug-resistant gram-negative infections, including <em>Acinetobacter</em> [<a href="#rid112">112</a>]. The higher dose was associated with better outcomes than standard dosing, particularly among those with ventilator-associated pneumonia, a finding that has been replicated in other studies as well [<a href="#rid113">113-116</a>].</p><p></p><p class="bulletIndent2">Clinical data regarding the use of <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> to treat <em>Acinetobacter </em>infections suggest that tigecycline may provide comparable outcomes compared with other regimens. A meta-analysis of 24 studies found no differences in all-cause mortality and clinical response with tigecycline versus comparators, but tigecycline was associated with a lower microbial eradication rate and a trend for longer hospitalization [<a href="#rid117">117</a>]. Overall, studies of tigecycline for <em>Acinetobacter </em>infections report clinical success rates of 47 to 81 percent [<a href="#rid118">118-120</a>].</p><p></p><p class="bulletIndent2">Emergence of <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> resistance while on therapy has been reported in <em>Acinetobacter</em> infections, with an occurrence rate of 12 percent in the aforementioned meta-analysis [<a href="#rid52">52,102,113,114,117</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other tetracycline-based agents</strong> – Although other broad-spectrum tetracyclines (eg, <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a>, <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a>) have some activity in vitro against resistant <em>A. baumannii</em>, we do not routinely use them because clinical experience is extremely limited [<a href="#rid121">121-126</a>]. We also do not use <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> because susceptibility breakpoints are not available, and the rate of resistance is higher than with the tetracycline derivatives [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antibiotics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">Cefiderocol</a> – We only use cefiderocol when other effective antibiotics are not an option, and we only use it as part of a combination regimen. Although most isolates of extensively resistant <em>A. baumannii</em> remain susceptible to cefiderocol (including those possessing OXA-type beta-lactamases), clinical experience is extremely limited [<a href="#rid127">127,128</a>]. Furthermore, a randomized trial comparing cefiderocol to best-available therapy for carbapenem-resistant gram-negative infections (including 54 patients with <em>A. baumannii</em> infections) found a trend toward higher all-cause mortality with cefiderocol (34 versus 18 percent), although clinical cure rates were comparable [<a href="#rid129">129</a>]. The mortality difference was more pronounced among patients with <em>Acinetobacter</em> spp infections (50 versus 18 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Emerging agents</strong> – New antimicrobials targeting multidrug-resistant <em>A. baumannii</em> are under development; certain agents are available in some countries, although clinical data informing their use for <em>A. baumannii</em> remain very limited [<a href="#rid130">130</a>]. Phage therapy has been promising as a novel therapeutic approach, but clinical data are limited to a few case reports [<a href="#rid131">131,132</a>].</p><p></p><p class="headingAnchor" id="H63685882"><span class="h2">Antibiotics that are not effective</span><span class="headingEndMark"> — </span>In general, <a class="drug drug_general" data-topicid="8477" href="/d/drug information/8477.html" rel="external">fosfomycin</a> and <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a> should not be used because <em>Acinetobacter </em>is usually intrinsically resistant to both agents [<a href="#rid49">49,50,133-137</a>]. For simple cystitis in the absence of systemic symptoms, some experts administer a trial of oral fosfomycin; however, there are no standardized breakpoints to determine susceptibility, and the United States Clinical and Laboratory Standards Institute expert panel on antibiotic resistance considers <em>A. baumannii </em>to be intrinsically resistant to fosfomycin [<a href="#rid134">134</a>]. Studies also suggest that rapid emergence of resistance can develop in patients on fosfomycin therapy [<a href="#rid133">133</a>].</p><p>Rifamycins (eg, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>) have activity, both in vitro and in animal studies, against <em>Acinetobacter</em>. However, benefit has not been proven in clinical studies. Three small trials compared monotherapy with <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> to combination colistin plus rifampin, and none found a benefit with the addition of rifampin [<a href="#rid138">138-140</a>]. Rifamycins have associated toxicities and numerous drug interactions. At this time, based on available data, we suggest not using rifamycins for monotherapy or as part of combination regimens, and our approach aligns with expert guidelines [<a href="#rid49">49,50</a>].</p><p>Novel antibiotics that should not be used because they have limited in vitro activity again<em>st Acinetobacter </em>include <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> and <a class="drug drug_general" data-topicid="118322" href="/d/drug information/118322.html" rel="external">plazomicin</a>. Furthermore, <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="114672" href="/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a>, and imipenem-relebactam should not be used because the addition of novel beta-lactamase inhibitors (avibactam, vaborbactam, and relebactam) does not confer additional activity beyond that of the primary agents (<a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, and <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>).</p><p class="headingAnchor" id="H2064672438"><span class="h2">Role of combination antibiotic therapy</span><span class="headingEndMark"> — </span>Combination therapy is often used to treat <em>Acinetobacter </em>and other multidrug-resistant pathogens. We suggest it for moderate to severe infections or if multidrug resistance is suspected, as discussed elsewhere. (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p>There are no definitive clinical data that demonstrate improved outcomes with combination versus monotherapy. However, for highly resistant <em>Acinetobacter </em>infections, limited available data suggest that combination therapy may be associated with improved outcomes [<a href="#rid139">139,141-143</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of over 300 adults with <em>Acinetobacter</em> ventilator-associated pneumonia, combination therapy (as opposed to monotherapy) was independently associated with lower 30-day mortality [<a href="#rid141">141</a>]. Among those with imipenem-resistant infections, 30-day mortality rates were lower with combination therapy than with monotherapy (52 versus 67 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another retrospective study that included 83 critically ill patients with extensively resistant <em>Acinetobacter</em> infections, therapy with <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> plus another agent was associated with a lower 30-day mortality rate than with polymyxin B monotherapy (42 versus 68 percent) [<a href="#rid142">142</a>].</p><p></p><p>For empiric therapy, combination regimens are frequently used to increase the odds that at least one antibiotic will be active against the isolate. While there are no clear clinical data to support this practice for <em>Acinetobacter</em> infections, studies in patients with sepsis due to various pathogens have found that delayed initiation of an antibiotic to which the pathogen is susceptible leads to worse outcomes [<a href="#rid144">144-149</a>]. Further information about the importance of appropriate and timely antibiotic therapy is found elsewhere. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Timing'</a>.)</p><p>Combination therapy is also sometimes used to decrease the risk of emergence of resistance while on therapy. Very few studies have been performed to evaluate this issue for <em>Acinetobacter</em> [<a href="#rid150">150</a>]. In a meta-analysis of eight trials that compared combination beta-lactam and aminoglycoside therapy with beta-lactam monotherapy for the treatment of infections caused by various organisms, combination therapy did not decrease the rate of emergent resistance (odds ratio 0.9, 95% CI 0.56-1.47) [<a href="#rid151">151</a>]. Among <em>Acinetobacter</em> infections specifically, there was no difference in the development of resistance between combination regimens and monotherapy (0 of 11 versus 1 of 22 infections, respectively).</p><p class="headingAnchor" id="H951132228"><span class="h1">MONITORING FOR EMERGENT RESISTANCE</span><span class="headingEndMark"> — </span>Because of the possibility of emergence of resistance during therapy, continued monitoring of the patient is important. If there is lack of expected improvement or a decline following an initial improvement, repeat cultures to evaluate for growth of resistant <em>Acinetobacter</em> isolates is warranted. While awaiting culture results, therapy can be changed to different agents, preferably from different classes, if clinically indicated.</p><p class="headingAnchor" id="H1211118"><span class="h1">DISEASE-SPECIFIC CONSIDERATIONS</span></p><p class="headingAnchor" id="H1211132"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>The management of pneumonia caused by <em>Acinetobacter</em> is the same as that for <em>Acinetobacter</em> infections in general, as described above (see <a class="local">'Suggested antibiotic regimens'</a> above). Additional considerations include the possible use of adjunctive inhaled antibiotics.</p><p>In select patients, inhaled <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> may be beneficial when combined with a systemic antibiotic [<a href="#rid94">94,152-154</a>], although not all studies suggest a benefit [<a href="#rid155">155</a>]. Because intravenous colistin yields low lung concentrations, we favor adding inhaled colistin for patients with serious pneumonia being treated with parenteral colistin. If other options are available, we avoid the use of polymyxins for pneumonia, whether intravenous or inhaled.</p><p>The optimal dose of inhaled <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> is uncertain. Our suggested doses match those in expert guidelines and can be seen in the table  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>) [<a href="#rid83">83,156</a>].</p><p>Among three studies evaluating inhaled <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> as adjunctive therapy to intravenous antibiotics for ventilator-associated pneumonia with drug-resistant gram-negative bacilli, predominantly <em>A. baumannii</em>, the pooled response rate was 80 percent [<a href="#rid94">94</a>]. The main adverse effect of inhaled colistin is bronchoconstriction [<a href="#rid95">95</a>].</p><p>Although there are reports of successful treatment of multidrug-resistant respiratory infections by combining inhaled and systemic <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> [<a href="#rid157">157</a>], we do not typically use inhaled polymyxin B because of the risk of bronchospasm. (See  <a class="medical medical_review" href="/d/html/486.html" rel="external">"Polymyxins: An overview", section on 'Inhaled administration'</a>.)</p><p>The duration of therapy is similar to that for other causes of pneumonia and is discussed separately. (See  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Duration of therapy'</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Duration'</a>.)</p><p class="headingAnchor" id="H1211146"><span class="h2">Bloodstream infection</span><span class="headingEndMark"> — </span>The management of bacteremia is typically the same as that for <em>Acinetobacter</em> infections in general.</p><p>Patients with primary bacteremia are typically maintained on combination therapy for the complete treatment course. For patients being transitioned from combination therapy to monotherapy (eg, patients whose bacteremia was secondary to urinary tract infection [UTI] or another nonsevere infection), we avoid <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> or <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> as monotherapy; both agents have low blood levels because they rapidly enter tissues following administration.</p><p>If bacteremia is associated with an intravascular catheter, the device should be removed [<a href="#rid158">158</a>].</p><p>The duration of therapy for uncomplicated bacteremia is similar to bacteremia due to other gram-negative pathogens and is discussed elsewhere (see  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Duration and route of therapy'</a> and  <a class="medical medical_review" href="/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a>). If endocarditis accompanies <em>Acinetobacter</em> bacteremia, duration of therapy is longer and additional considerations exist. (See  <a class="medical medical_review" href="/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'Other gram-negative organisms'</a> and  <a class="medical medical_review" href="/d/html/2141.html" rel="external">"Antimicrobial therapy of prosthetic valve endocarditis", section on 'Other gram-negative organisms'</a>.)</p><p class="headingAnchor" id="H1211160"><span class="h2">Meningitis</span><span class="headingEndMark"> — </span>Variable cerebrospinal fluid (CSF) penetration of antibiotic agents limits the therapeutic choices for <em>Acinetobacter</em> central nervous system infections.</p><p>Of the first-line agents, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, and the carbapenems most reliably enter into the CSF, particularly when inflammation of the meninges is minimal [<a href="#rid159">159</a>]. Because of the association between high-dose <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> and seizures, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> is the preferred choice of the carbapenems. More details regarding antibiotics used to treat gram-negative meningitis are found elsewhere. (See  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Systemic antimicrobial therapy'</a>.)</p><p>For carbapenem-resistant isolates, polymyxins have been used with some success [<a href="#rid159">159</a>]. Because intravenous <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> achieves spinal fluid levels of only 25 percent of serum levels, we add intrathecal (IT) or intraventricular (IVT) colistin for CNS infections being treated with an intravenous polymyxin [<a href="#rid92">92,159,160</a>].</p><p>The dose for IT and IVT <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> therapy varies widely in studies [<a href="#rid161">161-165</a>]. Complications include aseptic chemical meningitis or ventriculitis, which may cause increased CSF white blood cell counts and require IT or IVT dose reduction [<a href="#rid161">161</a>]. Dosing and more details regarding colistin IT and IVT polymyxin therapy are found elsewhere  (<a class="graphic graphic_table graphicRef71395" href="/d/graphic/71395.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Intrathecal and intraventricular therapy'</a>.)</p><p>The role of <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> in gram-negative bacillary <em>Acinetobacter </em>meningitis is limited, since tigecycline CSF penetration is only 11 percent of serum levels, and the CSF concentrations after intravenous administration do not reliably exceed the minimum inhibitory concentrations (MICs) of most <em>A. baumannii</em> strains [<a href="#rid166">166,167</a>]. Nevertheless, tigecycline, when used in combination with other antibiotics, has been used successfully to treat meningitis caused by multidrug-resistant <em>Acinetobacter</em> spp [<a href="#rid168">168,169</a>]. The role of <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> for treatment of meningitis is uncertain, and we only use it in combination therapy and only when no other options are available.</p><p>There are few clinical data on the treatment of meningitis with <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>. The fraction of the serum concentration that appears in the CSF following sulbactam administration has ranged from less than 1 percent in patients without meningitis to 33 percent in patients with meningitis [<a href="#rid170">170</a>].</p><p>Patients whose CNS infection is associated with a CNS device should undergo device removal [<a href="#rid171">171</a>].</p><p>For CNS infections due to <em>Acinetobacter</em>,<em> </em>especially those due to multidrug-resistant isolates, consultation with an expert in the management of such infections is advised. More detailed discussion of CNS infections due to gram-negative bacilli is found elsewhere. (See  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis"</a>.)</p><p>The response to therapy should be assessed clinically and with repeat CSF cultures, and the duration of therapy for <em>Acinetobacter</em> meningitis is similar to the duration for other gram-negative meningitis infections. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Follow-up CSF testing in selected cases'</a> and  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Duration'</a>.)</p><p class="headingAnchor" id="H1211167"><span class="h2">Skin, soft tissue, and bone infection</span><span class="headingEndMark"> — </span>The management of skin, soft tissue, and bone infections caused by <em>Acinetobacter</em> is the same as that for <em>Acinetobacter</em> infections in general, as described elsewhere (see <a class="local">'Suggested antibiotic regimens'</a> above). In addition, debridement of affected tissue, particularly in the case of osteomyelitis, may be necessary for optimal control of the infection.</p><p>The usual duration of therapy for skin and soft tissue infections is shorter than for osteomyelitis and joint infections. For <em>Acinetobacter </em>infections, duration typically matches that of similar infections caused by other pathogens. Details are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment"</a> and  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults", section on 'Duration'</a> and  <a class="medical medical_review" href="/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment", section on 'Duration of therapy'</a>.)</p><p class="headingAnchor" id="H1211174"><span class="h2">Urinary tract infection</span><span class="headingEndMark"> — </span>The management of UTIs caused by <em>Acinetobacter</em> is the same as that for <em>Acinetobacter</em> infections in general, except <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, and <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> should not be used as monotherapy because they have poor excretion into the urinary tract. If present, any urinary catheter should be removed.</p><p>Because <em>Acinetobacter</em> readily colonizes the urinary tract, particularly in the presence of an indwelling catheter, treatment for infection should only be initiated if a positive culture is accompanied by pyuria and systemic signs or symptoms in the absence of another source of infection. Details regarding differentiating colonization from infection are discussed above. (See <a class="local">'Differentiating colonization from infection'</a> above.)</p><p>The duration of therapy is the same as that for other bacterial UTIs, which are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females"</a> and  <a class="medical medical_review" href="/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Duration'</a>.)</p><p class="headingAnchor" id="H1211181"><span class="h2">Other infections</span><span class="headingEndMark"> — </span><em>Acinetobacter</em> infection of the eye can include corneal ulcers, endophthalmitis, periorbital cellulitis, and infection after penetrating trauma [<a href="#rid172">172-177</a>]. Treatment often consists of topical, subconjunctival, or intravitreal ophthalmic antibiotic preparations, guided by susceptibility results. The duration of treatment is generally similar to that for infections caused by other gram-negative bacilli and depends on the site of infection. (See  <a class="medical medical_review" href="/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a> and  <a class="medical medical_review" href="/d/html/3414.html" rel="external">"Orbital cellulitis"</a>.)</p><p><em>Acinetobacter</em> can cause nosocomial sinusitis in patients admitted to the intensive care unit; mechanical ventilation is the most important predisposing factor [<a href="#rid178">178,179</a>]. Treatment of <em>Acinetobacter</em> sinusitis consists of nasal tube removal, sinus drainage and lavage, and antibiotics and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1644.html" rel="external">"Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Sinusitis'</a>.)</p><p><em>Acinetobacter</em> peritonitis has been described in patients undergoing peritoneal dialysis [<a href="#rid180">180-182</a>]. The management of peritonitis in patients undergoing peritoneal dialysis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H1052126577"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Overall mortality from <em>Acinetobacter </em>infection is higher than that associated with most other gram-negative bacilli. In a systematic review of over 2500 patients with <em>Acinetobacter </em>infections from 16 observational studies, the overall mortality rate was 33 percent [<a href="#rid183">183</a>].</p><p>Infections due to resistant strains are associated with higher mortality [<a href="#rid183">183-185</a>]. In the aforementioned systematic review, carbapenem resistance was associated with a greater risk of death (pooled odds ratio 2.22, 95% CI 1.66-2.98) [<a href="#rid183">183</a>]. The excess mortality reported from resistant pathogens in this review may have been conflated due to presence of more severe underlying illness or receipt of inappropriate empiric antibiotic therapy in the group with resistant infections.</p><p class="headingAnchor" id="H11"><span class="h1">PREVENTION AND CONTROL</span><span class="headingEndMark"> — </span>The goals for control of multidrug-resistant <em>Acinetobacter</em> are early recognition, aggressive control of spread, and preventing establishment of endemic strains. General principles of infection control, as well as strategies to prevent health care-associated infections, are essential and are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3810.html" rel="external">"Nosocomial infections in the intensive care unit: Epidemiology and prevention"</a>.)</p><p>With regards to environmental cleansing, disinfection is particularly important because of the ability of <em>Acinetobacter</em> to survive on inanimate surfaces and contaminate other surfaces that come into contact with it [<a href="#rid186">186</a>]. As an example, in a study of 199 interactions between health care personnel and patients colonized with multidrug-resistant <em>Acinetobacter</em>, 39 percent resulted in contamination of gloves and/or gowns of the health care personnel, a more frequent rate than that observed for multidrug-resistant <em>Pseudomonas</em> [<a href="#rid187">187</a>]. Multidrug-resistant <em>Acinetobacter</em> remains largely susceptible to disinfectants and antiseptics; occasional reports of failure are more likely to represent failure of personnel to follow cleaning procedures than disinfectant resistance [<a href="#rid188">188</a>].</p><p>Control is most successful when a common source is identified and eliminated [<a href="#rid1">1,189</a>]. Aggressive and monitored cleaning of environmental reservoirs (using ultraviolet markers of cleaning efficacy) is also important [<a href="#rid189">189</a>]. Hydrogen peroxide vapor has been found to be an effective decontamination method [<a href="#rid190">190</a>]. When neither common sources nor environmental reservoirs are identified, control depends on active surveillance, contact isolation, health care worker compliance with hand hygiene, and aseptic care of vascular catheters and endotracheal tubes [<a href="#rid189">189,191</a>]. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p class="headingAnchor" id="H1214596"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic resistance</strong> – <em>Acinetobacter</em> is intrinsically resistant to numerous antibiotics and can accumulate additional mechanisms of resistance that limit antibiotic treatment options. (See <a class="local">'Antibiotic resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Globally, resistant strains have become increasingly common. Risk factors for resistance include healthcare exposure and prior exposure to certain antibiotics. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiating colonization from active infection</strong> – Colonization is common and should not be treated. Positive cultures from sterile sites (eg, blood, pleural fluid) should be interpreted as true infection. Cultures from nonsterile sites (eg, urine, lungs) should only be treated if there is clinical evidence of active infection. (See <a class="local">'Differentiating colonization from infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suggested antibiotic regimens</strong> – Regimen selection depends primarily on the severity of the infection and susceptibility of the isolate  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">We categorize potentially active antibiotics as first-line or second-line agents. First-line agents include certain beta-lactam antibiotics, carbapenems, and fluoroquinolones (aminoglycosides and <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> are first-line agents only for urinary tract infections [UTIs]). Second-line agents primarily include polymyxins (ie, <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> and <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a>) and certain <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivatives (<a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>)  (<a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>). (See <a class="local">'Antibiotic efficacy and safety'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild infections</strong> – These include UTIs and skin and soft tissue infections in the absence of severe sepsis or septic shock. Select cases of pneumonia may be categorized as mild if no systemic symptoms (eg, fever &gt;100.5°F/38°C, tachycardia, tachypnea), hypoxia, mechanical ventilation, or other concerning features are present. (See <a class="local">'Severity of infection'</a> above.)</p><p></p><p class="bulletIndent2">For patients with mild infection, we suggest treating with monotherapy with a first-line agent rather than combination therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice of agent depends on susceptibility, side effects, and site of infection  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>). (See <a class="local">'Mild infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe infections</strong> – These include any infection for which heightened clinical concern is present or the criteria for mild infection are not met. Examples include severe sepsis or septic shock, infections for which source control has not been achieved, or any infection other than UTI, skin and soft tissue infection, or mild pneumonia. (See <a class="local">'Severity of infection'</a> above.)</p><p></p><p class="bulletIndent2">For patients with moderate to severe infections, we suggest initial combination antibiotic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Limited data suggest that it is associated with lower mortality rates. We choose a combination regimen based on the isolate's antibiotic susceptibilities  (<a class="graphic graphic_algorithm graphicRef139618" href="/d/graphic/139618.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef72436" href="/d/graphic/72436.html" rel="external">table 2</a>). For most infections, we transition combination therapy to an active single agent once clinical improvement occurs. (See <a class="local">'Moderate to severe infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease-specific considerations</strong> – Depending on the site of infection (eg, lungs, blood, central nervous system), certain antibiotics should be avoided or adjunctive antibiotics (eg, inhaled formulations for pneumonia, intrathecal formulations for meningitis) may be beneficial. (See <a class="local">'Disease-specific considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for emergent resistance</strong> – Because of the possibility of emergence of resistance during therapy, patients who do not respond as expected to therapy should have repeat cultures to evaluate for growth of resistant <em>Acinetobacter</em> isolates. (See <a class="local">'Monitoring for emergent resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Overall mortality from <em>Acinetobacter </em>infection, especially from multidrug-resistant isolates, is higher than that associated with most other gram-negative bacilli. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and control</strong> – The goals for control of multidrug-resistant <em>Acinetobacter</em> are early recognition, aggressive control of spread, and preventing establishment of endemic strains. Environmental disinfection is particularly important because <em>Acinetobacter </em>can survive on inanimate surfaces and personal protective equipment worn by health care personnel. (See <a class="local">'Prevention and control'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692.</a></li><li><a class="nounderline abstract_t">Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50:2941.</a></li><li><a class="nounderline abstract_t">Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197:1079.</a></li><li><a class="nounderline abstract_t">De Rosa FG, Corcione S, Pagani N, Di Perri G. From ESKAPE to ESCAPE, from KPC to CCC. Clin Infect Dis 2015; 60:1289.</a></li><li><a class="nounderline abstract_t">Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18:318.</a></li><li><a class="nounderline abstract_t">Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268.</a></li><li class="breakAll">Centers for Disease Control and Prevention (CDC). Antimicrobial-resistant phenotype definitions, last updated 1/2022. https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/phenotype_definitions.pdf (Accessed on August 03, 2022).</li><li><a class="nounderline abstract_t">Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848.</a></li><li><a class="nounderline abstract_t">Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007; 57:207.</a></li><li><a class="nounderline abstract_t">Tatman-Otkun M, Gürcan S, Ozer B, Shokrylanbaran N. Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations. New Microbiol 2004; 27:21.</a></li><li><a class="nounderline abstract_t">Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97.</a></li><li><a class="nounderline abstract_t">Zhu X, Tong A, Wang D, et al. Antibiotic resistance patterns of Gram-negative and Gram-positive strains isolated from inpatients with nosocomial infections in a tertiary hospital in Beijing, China from 2011 to 2014. J Chemother 2016; :1.</a></li><li><a class="nounderline abstract_t">Logan LK, Gandra S, Trett A, et al. Acinetobacter baumannii Resistance Trends in Children in the United States, 1999-2012. J Pediatric Infect Dis Soc 2019; 8:136.</a></li><li><a class="nounderline abstract_t">Pournaras S, Markogiannakis A, Ikonomidis A, et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 2006; 57:557.</a></li><li><a class="nounderline abstract_t">Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007; 65:204.</a></li><li><a class="nounderline abstract_t">Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31:101.</a></li><li><a class="nounderline abstract_t">Peleg AY, Franklin C, Bell JM, Spelman DW. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect Control Hosp Epidemiol 2006; 27:759.</a></li><li><a class="nounderline abstract_t">Giske CG, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52:813.</a></li><li><a class="nounderline abstract_t">Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents 2011; 37:291.</a></li><li><a class="nounderline abstract_t">Freeman R, Moore LS, Charlett A, et al. Exploring the epidemiology of carbapenem-resistant Gram-negative bacteria in west London and the utility of routinely collected hospital microbiology data. J Antimicrob Chemother 2015; 70:1212.</a></li><li><a class="nounderline abstract_t">Van TD, Dinh QD, Vu PD, et al. Antibiotic susceptibility and molecular epidemiology of Acinetobacter calcoaceticus-baumannii complex strains isolated from a referral hospital in northern Vietnam. J Glob Antimicrob Resist 2014; 2:318.</a></li><li><a class="nounderline abstract_t">Jean SS, Hsueh PR, Lee WS, et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009; 33:266.</a></li><li><a class="nounderline abstract_t">Wang H, Chen M, Ni Y, et al. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents 2010; 35:227.</a></li><li><a class="nounderline abstract_t">Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004; 48:224.</a></li><li><a class="nounderline abstract_t">Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65:233.</a></li><li><a class="nounderline abstract_t">Sacco F, Visca P, Runci F, et al. Susceptibility Testing of Colistin for Acinetobacter baumannii: How Far Are We from the Truth? Antibiotics (Basel) 2021; 10.</a></li><li><a class="nounderline abstract_t">Moghnieh RA, Kanafani ZA, Tabaja HZ, et al. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis 2018; 18:e379.</a></li><li><a class="nounderline abstract_t">Kanj SS, Tayyar R, Shehab M, et al. Increased blaOXA-23-like prevalence in Acinetobacter baumannii at a tertiary care center in Lebanon (2007-2013). J Infect Dev Ctries 2018; 12:228.</a></li><li><a class="nounderline abstract_t">Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases 2014; 2:787.</a></li><li><a class="nounderline abstract_t">Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009; 65:414.</a></li><li><a class="nounderline abstract_t">Seifert H, Blondeau J, Lucaßen K, Utt EA. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018). J Glob Antimicrob Resist 2022; 31:82.</a></li><li><a class="nounderline abstract_t">Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010; 16:209.</a></li><li><a class="nounderline abstract_t">Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. J Hosp Med 2016; 11:21.</a></li><li><a class="nounderline abstract_t">Teerawattanapong N, Panich P, Kulpokin D, et al. A Systematic Review of the Burden of Multidrug-Resistant Healthcare-Associated Infections Among Intensive Care Unit Patients in Southeast Asia: The Rise of Multidrug-Resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol 2018; 39:525.</a></li><li><a class="nounderline abstract_t">Kanafani ZA, Zahreddine N, Tayyar R, et al. Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrob Resist Infect Control 2018; 7:9.</a></li><li><a class="nounderline abstract_t">Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38:4086.</a></li><li><a class="nounderline abstract_t">Tacconelli E, Cataldo MA, De Pascale G, et al. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J Antimicrob Chemother 2008; 62:1130.</a></li><li><a class="nounderline abstract_t">Dizbay M, Tunccan OG, Sezer BE, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis 2010; 42:741.</a></li><li><a class="nounderline abstract_t">Vitkauskiene A, Dambrauskiene A, Cerniauskiene K, et al. Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection. Scand J Infect Dis 2013; 45:213.</a></li><li><a class="nounderline abstract_t">Karruli A, Boccia F, Gagliardi M, et al. Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience. Microb Drug Resist 2021; 27:1167.</a></li><li><a class="nounderline abstract_t">Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2:S43.</a></li><li><a class="nounderline abstract_t">Hsueh PR, Teng LJ, Chen CY, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002; 8:827.</a></li><li><a class="nounderline abstract_t">Mugnier P, Poirel L, Pitout M, Nordmann P. Carbapenem-resistant and OXA-23-producing Acinetobacter baumannii isolates in the United Arab Emirates. Clin Microbiol Infect 2008; 14:879.</a></li><li><a class="nounderline abstract_t">Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2:S49.</a></li><li><a class="nounderline abstract_t">Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380.</a></li><li><a class="nounderline abstract_t">Peleg AY, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065.</a></li><li><a class="nounderline abstract_t">Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009; 53:3628.</a></li><li><a class="nounderline abstract_t">Superti SV, Martins Dde S, Caierão J, et al. Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration. Rev Inst Med Trop Sao Paulo 2009; 51:111.</a></li><li class="breakAll">Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0. Published on 3/31/2022. https://www.idsociety.org/practice-guideline/amr-guidance-2.0/#toc-9.</li><li><a class="nounderline abstract_t">Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 2022; 28:521.</a></li><li><a class="nounderline abstract_t">Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018; 18:391.</a></li><li><a class="nounderline abstract_t">Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis 2010; 51:79.</a></li><li><a class="nounderline abstract_t">Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49:479.</a></li><li><a class="nounderline abstract_t">Cisneros JM, Reyes MJ, Pachón J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22:1026.</a></li><li><a class="nounderline abstract_t">Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001; 21:142.</a></li><li><a class="nounderline abstract_t">Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003; 54:32.</a></li><li><a class="nounderline abstract_t">Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56:432.</a></li><li><a class="nounderline abstract_t">Makris D, Petinaki E, Tsolaki V, et al. Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study. Indian J Crit Care Med 2018; 22:67.</a></li><li><a class="nounderline abstract_t">Pourheidar E, Haghighi M, Kouchek M, et al. Comparison of Intravenous Ampicillin-sulbactam Plus Nebulized Colistin with Intravenous Colistin Plus Nebulized Colistin in Treatment of Ventilator Associated Pneumonia Caused by Multi Drug Resistant Acinetobacter Baumannii: Randomized Open Label Trial. Iran J Pharm Res 2019; 18:269.</a></li><li><a class="nounderline abstract_t">Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425.</a></li><li><a class="nounderline abstract_t">Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61:1369.</a></li><li><a class="nounderline abstract_t">Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis. J Glob Antimicrob Resist 2021; 24:136.</a></li><li><a class="nounderline abstract_t">Jung SY, Lee SH, Lee SY, et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care 2017; 21:319.</a></li><li><a class="nounderline abstract_t">Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007; 39:38.</a></li><li><a class="nounderline abstract_t">Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021. Antimicrob Agents Chemother 2022; 66:e0078122.</a></li><li><a class="nounderline abstract_t">Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 2023; 23:1072.</a></li><li><a class="nounderline abstract_t">Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148.</a></li><li><a class="nounderline abstract_t">Lesho E, Wortmann G, Moran K, Craft D. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility. Clin Infect Dis 2005; 41:758.</a></li><li><a class="nounderline abstract_t">Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45:1915.</a></li><li><a class="nounderline abstract_t">Rit K, Saha R. Multidrug-resistant acinetobacter infection and their susceptibility patterns in a tertiary care hospital. Niger Med J 2012; 53:126.</a></li><li><a class="nounderline abstract_t">Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52:331.</a></li><li><a class="nounderline abstract_t">Itabashi S. [Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia]. Jpn J Antibiot 2007; 60:161.</a></li><li><a class="nounderline abstract_t">Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089.</a></li><li><a class="nounderline abstract_t">Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2009; 33:290.</a></li><li><a class="nounderline abstract_t">Spence RP, Towner KJ. Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003; 52:687.</a></li><li><a class="nounderline abstract_t">Heinemann B, Wisplinghoff H, Edmond M, Seifert H. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains. Antimicrob Agents Chemother 2000; 44:2211.</a></li><li class="breakAll">European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters, Version 12.0, valid from 2022-01-01. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf (Accessed on August 24, 2022).</li><li class="breakAll">CLSI M100-ED32:2022 Performance standards for antimicrobial susceptibility testing, 32nd edition. http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED32:2022&amp;scope=user (Accessed on August 24, 2022).</li><li><a class="nounderline abstract_t">Aliakbarzade K, Farajnia S, Karimi Nik A, et al. Prevalence of Aminoglycoside Resistance Genes in Acinetobacter baumannii Isolates. Jundishapur J Microbiol 2014; 7:e11924.</a></li><li><a class="nounderline abstract_t">Liu JY, Wang FD, Ho MW, et al. In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan. J Microbiol Immunol Infect 2016; 49:918.</a></li><li><a class="nounderline abstract_t">Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence. Int J Antimicrob Agents 2015; 46:231.</a></li><li><a class="nounderline abstract_t">Núñez ML, Martínez-Toldos MC, Bru M, et al. Appearance of resistance to meropenem during the treatment of a patient with meningitis by Acinetobacter. Scand J Infect Dis 1998; 30:421.</a></li><li><a class="nounderline abstract_t">Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10.</a></li><li><a class="nounderline abstract_t">Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010; 138:1333.</a></li><li><a class="nounderline abstract_t">Boisson M, Jacobs M, Grégoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 2014; 58:7331.</a></li><li><a class="nounderline abstract_t">Qureshi ZA, Hittle LE, O'Hara JA, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 2015; 60:1295.</a></li><li><a class="nounderline abstract_t">Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43 Suppl 2:S89.</a></li><li><a class="nounderline abstract_t">Horton J, Pankey GA. Polymyxin B, colistin, and sodium colistimethate. Med Clin North Am 1982; 66:135.</a></li><li><a class="nounderline abstract_t">Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55:49.</a></li><li><a class="nounderline abstract_t">Dickstein Y, Lellouche J, Schwartz D, et al. Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. Clin Infect Dis 2020; 71:2599.</a></li><li><a class="nounderline abstract_t">Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67:1607.</a></li><li><a class="nounderline abstract_t">Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008.</a></li><li><a class="nounderline abstract_t">Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111.</a></li><li><a class="nounderline abstract_t">Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54:670.</a></li><li><a class="nounderline abstract_t">Falagas ME, Kasiakou SK. Toxicity of Polymyxins: A Systematic Review of the Evidence from Old and Recent Studies. Crit Care 2006; 10:R27.</a></li><li><a class="nounderline abstract_t">Flamm RK, Castanheira M, Streit JM, Jones RN. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagn Microbiol Infect Dis 2016; 85:352.</a></li><li><a class="nounderline abstract_t">Flamm RK, Shortridge D, Castanheira M, et al. In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Tucker H, Wible M, Gandhi A, Quintana A. Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials. Infect Drug Resist 2017; 10:401.</a></li><li><a class="nounderline abstract_t">Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis 2014; 59 Suppl 6:S367.</a></li><li><a class="nounderline abstract_t">Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections. Clin Infect Dis 2014; 59 Suppl 6:S381.</a></li><li><a class="nounderline abstract_t">Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 2014; 59 Suppl 6:S374.</a></li><li><a class="nounderline abstract_t">Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 2010; 25:343.</a></li><li><a class="nounderline abstract_t">Falagas ME, Vardakas KZ, Kapaskelis A, et al. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents 2015; 45:455.</a></li><li class="breakAll">Sandhu R, Dahiya S, Sayal P. Evaluation of multiple antibiotic resistance (MAR) index and doxycycline susceptibility of Acinetobacter species among inpatients. Indian J MIcrobiol Res 2016; 3(3): 299-304. https://d1wqtxts1xzle7.cloudfront.net/49562357/IJMR_33_299-304-with-cover-page-v2.pdf?Expires=1661381303&amp;Signature=hBAoJQhWLSaURNT3LM5s0V3P1CQwK~A2901qLr5yK5ODLyC55ZMwyNF6ld2AYTg41br~f8jI6yf5H2RR8OFvfjPaR~FJ6OpsWeLXj50VQHehkf-EeBbNSq~6VnKUdGYm5ndzQIX3YlN46wN3yUX9JBOXxxC-8s4l2VkACU~5RVicMsWaqd4lUuFZe (Accessed on August 24, 2022).</li><li><a class="nounderline abstract_t">Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59:128.</a></li><li><a class="nounderline abstract_t">Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58:1099.</a></li><li><a class="nounderline abstract_t">Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62:45.</a></li><li><a class="nounderline abstract_t">Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59:772.</a></li><li><a class="nounderline abstract_t">Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46:567.</a></li><li><a class="nounderline abstract_t">Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 2013; 32:1211.</a></li><li><a class="nounderline abstract_t">Vivo A, Fitzpatrick MA, Suda KJ, et al. Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study. BMC Infect Dis 2022; 22:491.</a></li><li><a class="nounderline abstract_t">De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014; 18:R90.</a></li><li class="breakAll">FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed on July 11, 2012).</li><li><a class="nounderline abstract_t">Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.</a></li><li><a class="nounderline abstract_t">Zha L, Pan L, Guo J, et al. Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. Adv Ther 2020; 37:1049.</a></li><li><a class="nounderline abstract_t">Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine (Baltimore) 2018; 97:e12467.</a></li><li><a class="nounderline abstract_t">Ni W, Han Y, Zhao J, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents 2016; 47:107.</a></li><li><a class="nounderline abstract_t">Kim WY, Moon JY, Huh JW, et al. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients. PLoS One 2016; 11:e0150642.</a></li><li><a class="nounderline abstract_t">Metan G, Alp E, Yildiz O, et al. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J Chemother 2010; 22:110.</a></li><li><a class="nounderline abstract_t">Curcio D, Fernández F, Vergara J, et al. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009; 21:58.</a></li><li><a class="nounderline abstract_t">Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents 2018; 51:62.</a></li><li><a class="nounderline abstract_t">Livermore DM, Mushtaq S, Warner M, Woodford N. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 2016; 60:3840.</a></li><li><a class="nounderline abstract_t">Abdallah M, Olafisoye O, Cortes C, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2015; 59:1802.</a></li><li><a class="nounderline abstract_t">Noel AR, Attwood M, Bowker KE, MacGowan AP. In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. J Antimicrob Chemother 2021; 76:667.</a></li><li><a class="nounderline abstract_t">Dong D, Zheng Y, Chen Q, et al. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018. Eur J Clin Microbiol Infect Dis 2020; 39:1559.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents 2019; 53:177.</a></li><li><a class="nounderline abstract_t">Sansone P, Giaccari LG, Coppolino F, et al. Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence. Antibiotics (Basel) 2022; 11.</a></li><li><a class="nounderline abstract_t">Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21:226.</a></li><li><a class="nounderline abstract_t">Isler B, Doi Y, Bonomo RA, Paterson DL. New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Schooley RT, Biswas B, Gill JJ, et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1:66.</a></li><li><a class="nounderline abstract_t">Sharma A, Sharma R, Bhattacharyya T, et al. Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter-AbaF. J Antimicrob Chemother 2017; 72:68.</a></li><li class="breakAll">CLSI M100-ED32:2022 Performance standards for antimicrobial susceptibility testing, 32nd edition. Appendix B: Intrinsic resistance. http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED32:2022&amp;sbssok=CLSI%20M100%20ED32:2022%20APPENDIX%20B&amp;format=HTML&amp;hl=acinetobacter (Accessed on August 24, 2022).</li><li><a class="nounderline abstract_t">Silver LL. Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med 2017; 7.</a></li><li><a class="nounderline abstract_t">Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016; 29:321.</a></li><li><a class="nounderline abstract_t">Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012; 67:255.</a></li><li><a class="nounderline abstract_t">Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57:349.</a></li><li><a class="nounderline abstract_t">Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141:1214.</a></li><li><a class="nounderline abstract_t">Park HJ, Cho JH, Kim HJ, et al. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist 2019; 17:66.</a></li><li><a class="nounderline abstract_t">Özvatan T, Akalın H, Sınırtaş M, et al. Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases. Respirology 2016; 21:363.</a></li><li><a class="nounderline abstract_t">Rigatto MH, Vieira FJ, Antochevis LC, et al. Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother 2015; 59:6575.</a></li><li><a class="nounderline abstract_t">Kuo LC, Lai CC, Liao CH, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007; 13:196.</a></li><li><a class="nounderline abstract_t">Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045.</a></li><li><a class="nounderline abstract_t">Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742.</a></li><li><a class="nounderline abstract_t">Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146.</a></li><li><a class="nounderline abstract_t">Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529.</a></li><li><a class="nounderline abstract_t">Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069.</a></li><li><a class="nounderline abstract_t">Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237.</a></li><li><a class="nounderline abstract_t">Kmeid JG, Youssef MM, Kanafani ZA, Kanj SS. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther 2013; 11:1355.</a></li><li><a class="nounderline abstract_t">Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41:149.</a></li><li><a class="nounderline abstract_t">Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754.</a></li><li><a class="nounderline abstract_t">Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care 2016; 6:26.</a></li><li><a class="nounderline abstract_t">Zheng JY, Huang SS, Huang SH, Ye JJ. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Microbiol Immunol Infect 2020; 53:854.</a></li><li><a class="nounderline abstract_t">Demirdal T, Sari US, Nemli SA. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? Ann Clin Microbiol Antimicrob 2016; 15:11.</a></li><li><a class="nounderline abstract_t">Lu Q, Luo R, Bodin L, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012; 117:1335.</a></li><li><a class="nounderline abstract_t">Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007; 58:235.</a></li><li><a class="nounderline abstract_t">Hanna H, Afif C, Alakech B, et al. Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse. Infect Control Hosp Epidemiol 2004; 25:646.</a></li><li><a class="nounderline abstract_t">Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009; 9:245.</a></li><li><a class="nounderline abstract_t">Jiménez-Mejías ME, Pichardo-Guerrero C, Márquez-Rivas FJ, et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:212.</a></li><li><a class="nounderline abstract_t">Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006; 58:1078.</a></li><li><a class="nounderline abstract_t">Al Shirawi N, Memish ZA, Cherfan A, Al Shimemeri A. Post-neurosurgical meningitis due to multidrug-resistant Acinetobacter baumanii treated with intrathecal colistin: case report and review of the literature. J Chemother 2006; 18:554.</a></li><li><a class="nounderline abstract_t">Benifla M, Zucker G, Cohen A, Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 2004; 54:290.</a></li><li><a class="nounderline abstract_t">Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 2005; 43:4916.</a></li><li><a class="nounderline abstract_t">Fernandez-Viladrich P, Corbella X, Corral L, et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999; 28:916.</a></li><li><a class="nounderline abstract_t">Ray L, Levasseur K, Nicolau DP, Scheetz MH. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother 2010; 44:582.</a></li><li><a class="nounderline abstract_t">Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221.</a></li><li><a class="nounderline abstract_t">Tutuncu EE, Kuscu F, Gurbuz Y, et al. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis 2010; 14 Suppl 3:e224.</a></li><li><a class="nounderline abstract_t">Sipahi OR, Mermer S, Demirdal T, et al. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study. Clin Neurol Neurosurg 2018; 172:31.</a></li><li><a class="nounderline abstract_t">Nau R, Djukic M, Spreer A, et al. Bacterial meningitis: an update of new treatment options. Expert Rev Anti Infect Ther 2015; 13:1401.</a></li><li><a class="nounderline abstract_t">Rodríguez Guardado A, Maradona JA, Asensi V, et al. [Postsurgical meningitis caused by Acinetobacter baumannii: study of 22 cases and review of the literature]. Rev Clin Esp 2001; 201:497.</a></li><li><a class="nounderline abstract_t">Wang AG, Wu CC, Liu JH. Bacterial corneal ulcer: a multivariate study. Ophthalmologica 1998; 212:126.</a></li><li><a class="nounderline abstract_t">Gopal L, Ramaswamy AA, Madhavan HN, et al. Postoperative endophthalmitis caused by sequestered Acinetobacter calcoaceticus. Am J Ophthalmol 2000; 129:388.</a></li><li><a class="nounderline abstract_t">Mahajan VM. Postoperative ocular infections: an analysis of laboratory data on 750 cases. Ann Ophthalmol 1984; 16:847.</a></li><li><a class="nounderline abstract_t">Mark DB, Gaynon MW. Trauma-induced endophthalmitis caused by Acinetobacter anitratus. Br J Ophthalmol 1983; 67:124.</a></li><li><a class="nounderline abstract_t">Miller J. Acinetobacter as a causative agent in preseptal cellulitis. Optometry 2005; 76:176.</a></li><li><a class="nounderline abstract_t">Mathews D, Mathews JP, Kwartz J, Inkster C. Preseptal cellulitis caused by Acinetobacter lwoffi. Indian J Ophthalmol 2005; 53:213.</a></li><li><a class="nounderline abstract_t">Bert F, Lambert-Zechovsky N. Sinusitis in mechanically ventilated patients and its role in the pathogenesis of nosocomial pneumonia. Eur J Clin Microbiol Infect Dis 1996; 15:533.</a></li><li><a class="nounderline abstract_t">Pneumatikos I, Konstantonis D, Tsagaris I, et al. Prevention of nosocomial maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists and corticosteroids. Intensive Care Med 2006; 32:532.</a></li><li><a class="nounderline abstract_t">Dandecha P, Sangthawan P. Peritonitis in acute peritoneal dialysis in a university hospital. J Med Assoc Thai 2002; 85:477.</a></li><li><a class="nounderline abstract_t">Galvao C, Swartz R, Rocher L, et al. Acinetobacter peritonitis during chronic peritoneal dialysis. Am J Kidney Dis 1989; 14:101.</a></li><li><a class="nounderline abstract_t">Valdez JM, Asperilla MO, Smego RA Jr. Acinetobacter peritonitis in patients receiving continuous ambulatory peritoneal dialysis. South Med J 1991; 84:607.</a></li><li><a class="nounderline abstract_t">Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 2014; 20:416.</a></li><li><a class="nounderline abstract_t">Kim T, Lee EJ, Park SY, et al. Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: A retrospective multicenter study in Korea. Medicine (Baltimore) 2018; 97:e12984.</a></li><li><a class="nounderline abstract_t">Wu D, Chen C, Liu T, et al. Epidemiology, Susceptibility, and Risk Factors Associated with Mortality in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Abdominal Solid Organ Transplant Recipients: A Retrospective Cohort Study. Infect Dis Ther 2021; 10:559.</a></li><li><a class="nounderline abstract_t">Wendt C, Dietze B, Dietz E, Rüden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997; 35:1394.</a></li><li><a class="nounderline abstract_t">Morgan DJ, Liang SY, Smith CL, et al. Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers. Infect Control Hosp Epidemiol 2010; 31:716.</a></li><li><a class="nounderline abstract_t">Hartstein AI, Rashad AL, Liebler JM, et al. Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags. Am J Med 1988; 85:624.</a></li><li><a class="nounderline abstract_t">Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24:284.</a></li><li><a class="nounderline abstract_t">Otter JA, Yezli S, Schouten MA, et al. Hydrogen peroxide vapor decontamination of an intensive care unit to remove environmental reservoirs of multidrug-resistant gram-negative rods during an outbreak. Am J Infect Control 2010; 38:754.</a></li><li><a class="nounderline abstract_t">Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36:1268.</a></li></ol></div><div id="topicVersionRevision">Topic 3150 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16447117" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The epidemiology and control of Acinetobacter baumannii in health care facilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940085" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419525" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25537879" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : From ESKAPE to ESCAPE, from KPC to CCC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29276051" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793988" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793988" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16107985" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Overview of nosocomial infections caused by gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949243" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14964402" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17370521" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27347770" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antibiotic resistance patterns of Gram-negative and Gram-positive strains isolated from inpatients with nosocomial infections in a tertiary hospital in Beijing, China from 2011 to 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29579216" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acinetobacter baumannii Resistance Trends in Children in the United States, 1999-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16431857" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254667" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10913404" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16807854" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070961" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical and economic impact of common multidrug-resistant gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21382699" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High burden of antimicrobial resistance in Asia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25525198" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Exploring the epidemiology of carbapenem-resistant Gram-negative bacteria in west London and the utility of routinely collected hospital microbiology data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540720" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antibiotic susceptibility and molecular epidemiology of Acinetobacter calcoaceticus-baumannii complex strains isolated from a referral hospital in northern Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19091522" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047820" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693543" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996144" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Global spread of carbapenem-resistant Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33466515" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Susceptibility Testing of Colistin for Acinetobacter baumannii: How Far Are We from the Truth?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30292478" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Epidemiology of common resistant bacterial pathogens in the countries of the Arab League.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851631" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Increased blaOXA-23-like prevalence in Acinetobacter baumannii at a tertiary care center in Lebanon (2007-2013).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25516853" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833471" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35948242" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20707714" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26353076" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29580299" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A Systematic Review of the Burden of Multidrug-Resistant Healthcare-Associated Infections Among Intensive Care Unit Patients in Southeast Asia: The Rise of Multidrug-Resistant Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29387343" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11060073" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635519" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20500117" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23113773" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33600262" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894514" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12141969" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18844691" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Carbapenem-resistant and OXA-23-producing Acinetobacter baumannii isolates in the United Arab Emirates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894515" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673804" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The new beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420217" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528270" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19390741" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19390741" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34923128" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29456043" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20504234" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of Acinetobacter infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11864948" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8783704" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213849" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767844" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501431" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29531445" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32802106" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of Intravenous Ampicillin-sulbactam Plus Nebulized Colistin with Intravenous Colistin Plus Nebulized Colistin in Treatment of Ventilator Associated Pneumonia Caused by Multi Drug Resistant Acinetobacter Baumannii: Randomized Open Label Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015687" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18367459" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32889142" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29262831" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17366011" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36005804" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37182534" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964033" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080102" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11353653" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293410" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Multidrug-resistant acinetobacter infection and their susceptibility patterns in a tertiary care hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917243" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Properties and potential of ertapenem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17867490" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : [Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18379232" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19091523" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12951327" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898706" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898706" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898706" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25632323" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Prevalence of Aminoglycoside Resistance Genes in Acinetobacter baumannii Isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26364729" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070662" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817528" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Appearance of resistance to meropenem during the treatment of a patient with meningitis by Acinetobacter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30710469" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558557" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267660" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25632010" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894521" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6278236" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Polymyxin B, colistin, and sodium colistimethate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17250897" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31758195" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22441575" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452626" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715304" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22322268" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507149" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Toxicity of Polymyxins: A Systematic Review of the Evidence from Old and Recent Studies</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27112832" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427295" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29138583" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25371512" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25371514" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25371513" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837632" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801348" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Tetracyclines for multidrug-resistant Acinetobacter baumannii infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801348" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Tetracyclines for multidrug-resistant Acinetobacter baumannii infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17082201" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16980293" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436554" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353223" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199038" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553594" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35610601" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24887101" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24887101" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467668" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Excess deaths associated with tigecycline after approval based on noninferiority trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32006240" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30235740" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26742726" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26934182" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20435570" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19297274" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28705668" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27044556" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25534744" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33294925" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356026" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32071045" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30395986" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35884158" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058795" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30323035" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28807909" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22334863" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Phage treatment of human infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27650185" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter-AbaF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27650185" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter-AbaF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28062557" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Fosfomycin: Mechanism and Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26960938" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Fosfomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22096042" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23616495" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22954403" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476654" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26635315" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26259799" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17328733" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048677" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668610" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893372" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599631" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763516" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696123" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24168069" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Combination therapy for Gram-negative bacteria: what is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983909" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080101" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27033711" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31607573" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26911714" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23132092" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350201" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15357155" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324297" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Management of meningitis due to antibiotic-resistant Acinetobacter species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11957024" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16916866" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17127235" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Post-neurosurgical meningitis due to multidrug-resistant Acinetobacter baumanii treated with intrathecal colistin: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15190037" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16145177" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10825065" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179255" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17012300" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19962335" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29960893" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293166" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Bacterial meningitis: an update of new treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692403" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : [Postsurgical meningitis caused by Acinetobacter baumannii: study of 22 cases and review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486553" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Bacterial corneal ulcer: a multivariate study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10704562" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Postoperative endophthalmitis caused by sequestered Acinetobacter calcoaceticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6439098" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Postoperative ocular infections: an analysis of laboratory data on 750 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6600400" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Trauma-induced endophthalmitis caused by Acinetobacter anitratus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15786636" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Acinetobacter as a causative agent in preseptal cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16137978" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Preseptal cellulitis caused by Acinetobacter lwoffi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874069" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Sinusitis in mechanically ventilated patients and its role in the pathogenesis of nosocomial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16501948" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Prevention of nosocomial maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists and corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118495" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Peritonitis in acute peritoneal dialysis in a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2757017" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Acinetobacter peritonitis during chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2035081" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Acinetobacter peritonitis in patients receiving continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24131374" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30412128" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: A retrospective multicenter study in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33611687" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Epidemiology, Susceptibility, and Risk Factors Associated with Mortality in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Abdominal Solid Organ Transplant Recipients: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9163451" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Survival of Acinetobacter baumannii on dry surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20486855" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3189366" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12725359" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Acinetobacter outbreaks, 1977-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20605263" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Hydrogen peroxide vapor decontamination of an intensive care unit to remove environmental reservoirs of multidrug-resistant gram-negative rods during an outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746772" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
